Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma, Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component

In brief

The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.

Key facts

Study ID

NCT00807495

Run by

Millennium Pharmaceuticals, Inc.

People needed

48

Starts

2009-02-10

Expected to finish

2013-02-13

Last updated by the study team

2018-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hematology Oncology Associates, Virtua Memorial Hospital Burlington County — Mount Holly, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.